摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Ethyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylate | 51986-17-5

中文名称
——
中文别名
——
英文名称
Ethyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylate
英文别名
3-ethoxycarbonyl-5-hydroxy-1-methylpyrazole;3-ethoxycarbonyl-1-methylpyrazolin-5-one;3-carboethoxy-1-methylpyrazol-5-one;1-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester;5-hydroxy-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester;5-Hydroxy-1-methyl-3-pyrazolcarbonsaeure-aethylester
Ethyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylate化学式
CAS
51986-17-5
化学式
C7H10N2O3
mdl
MFCD09839084
分子量
170.168
InChiKey
DGKFSQSYGNVCAA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    140-141 °C
  • 沸点:
    337.2±22.0 °C(Predicted)
  • 密度:
    1.29±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.73
  • 重原子数:
    12.0
  • 可旋转键数:
    3.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.428
  • 拓扑面积:
    64.35
  • 氢给体数:
    1.0
  • 氢受体数:
    3.0

安全信息

  • 海关编码:
    2933199090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    室温且干燥

SDS

SDS:7d73868ce14931aaebfcea387a818b18
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Ethyl 5-hydroxy-1-methyl-1h-pyrazole-3-carboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 5-hydroxy-1-methyl-1h-pyrazole-3-carboxylate
CAS number: 51986-17-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O3
Molecular weight: 170.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Ethyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylatesodium hydroxide盐酸 作用下, 以 为溶剂, 反应 5.0h, 以59%的产率得到2-methyl-3-oxo-1H-pyrazole-5-carboxylic acid
    参考文献:
    名称:
    WO2008/47071
    摘要:
    公开号:
  • 作为产物:
    描述:
    2-(1-Methylhydrazino)maleinsaeurediethylester 以95%的产率得到
    参考文献:
    名称:
    SUCROW W.; LUEBBE F.; FEHLAUER A., CHEM. BER., 1979, 112, NO 5, 1712-1718
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
    申请人:YUMANITY THERAPEUTICS INC
    公开号:WO2020198026A1
    公开(公告)日:2020-10-01
    The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    本发明涉及对神经系统疾病和原发性脑癌治疗中有用的化合物。本发明的化合物,单独或与其他药用活性剂结合使用,可用于治疗或预防神经系统疾病和原发性脑癌。
  • [EN] COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR PRODUIRE UN CONJUGUÉ
    申请人:REDWOOD BIOSCIENCE INC
    公开号:WO2014074218A1
    公开(公告)日:2014-05-15
    The present disclosure provides conjugate structures and compound structures used to produce these conjugates. Also provided are methods of producing drug-polypeptide or detectable label-polypeptide conjugates linked through a modified amino acid. Structures of the modified amino acids used in producing the conjugates are disclosed.
    本公开提供了用于制备这些共轭物的共轭结构和化合物结构。还提供了通过修饰的氨基酸连接的药物-多肽或可检测标记-多肽共轭物的制备方法。公开了用于制备共轭物的修饰氨基酸的结构。
  • [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS<br/>[FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS
    申请人:AICURIS GMBH & CO KG
    公开号:WO2013110643A1
    公开(公告)日:2013-08-01
    The present invention relates to novel β-lactam compounds of formula (I), their preparation and use. In particular, this invention relates to novel β-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.
    本发明涉及式(I)的新型β-内酰胺化合物,它们的制备和使用。特别是,本发明涉及作为抗菌剂有用的新型β-内酰胺化合物,即取代脒的单巴坦衍生物及其制备方法。
  • Positive allosteric modulators of nicotinic acetylcholine receptor
    申请人:Sams Anette Graven
    公开号:US20120252853A1
    公开(公告)日:2012-10-04
    The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
    本发明涉及在治疗中有用的化合物,包括含有该化合物的组合物,以及包括给予该化合物的治疗方法。所涉及的化合物是尼古丁乙酰胆碱α7受体的正向变构调节剂(PAMs)。
  • [EN] HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE WDR5 UTILISÉS EN TANT QUE COMPOSÉS ANTICANCÉREUX
    申请人:NOVARTIS AG
    公开号:WO2021028806A1
    公开(公告)日:2021-02-18
    The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.
    本发明提供了式(I)的化合物或其药学上可接受的盐;(I)这些化合物是WDR5的抑制剂。本发明还提供了包含这些化合物的药物组合物,包含这些化合物与额外治疗剂的组合物以及这些化合物的治疗用途。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺